Prediction of boron concentrations in blood from patients on boron neutron capture therapy

被引:0
作者
Shibata, Y
Matsumura, A [1 ]
Yamamoto, T
Akutsu, H
Yasuda, S
Nakai, K
Nose, T
Yamamoto, K
Kumada, H
Hori, N
Ohtake, S
机构
[1] Univ Tsukuba, Dept Neurosurg, Tsukuba, Ibaraki 3058575, Japan
[2] Japan Atom Energy Res Inst, Tokai, Ibaraki 3191195, Japan
关键词
boron neutron capture therapy; BSH; glioblastoma; prompt gamma ray analysis; radiation therapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In boron neutron capture therapy, blood boron concentration is the key factor to calculate radiation dose, however, blood sampling is difficult during neutron irradiation. Materials and Methods: The prediction of blood boron concentrations for BNCT treatment planning has been prospectively investigated using patient data obtained at first craniotomy after the infusion of a low dose of sodium undecahydroclosododecaborate. Results: The boron biodistribution data showed a biexponential pharmacokinetic profile. If the final boron concentration at 6 or 9 hours after the end of the infusion is within the 95% confidence interval of the prediction, direct prediction from biexponential fit will reduce the error of blood boron concentrations during irradiation to around 6%. Conclusion: Actual boron concentrations during BNCT were reasonably and accurately predictable from the test data.
引用
收藏
页码:5231 / 5235
页数:5
相关论文
共 21 条
[1]   Boron neutron capture therapy of brain tumors: An emerging therapeutic modality [J].
Barth, RF ;
Soloway, AH ;
Goodman, JH ;
Gahbauer, RA ;
Gupta, N ;
Blue, TE ;
Yang, WL ;
Tjarks, W .
NEUROSURGERY, 1999, 44 (03) :433-450
[2]   PERFORMANCE OF SULFHYDRYL BORON HYDRIDE IN PATIENTS WITH GRADE-III AND GRADE-IV ASTROCYTOMA - A BASIS FOR BORON NEUTRON-CAPTURE THERAPY [J].
CEBERG, CP ;
PERSSON, A ;
BRUN, A ;
HUISKAMP, R ;
FYHR, AS ;
PERSSON, BRR ;
SALFORD, LG .
JOURNAL OF NEUROSURGERY, 1995, 83 (01) :79-85
[3]   Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory [J].
Chadha, M ;
Capala, J ;
Coderre, JA ;
Elowitz, EH ;
Iwai, J ;
Joel, DD ;
Liu, HYB ;
Wielopolski, L ;
Chanana, AD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (04) :829-834
[4]   Boron neutron capture therapy for glioblastoma multiforme: Interim results from the Phase I/II dose-escalation studies [J].
Chanana, AD ;
Capala, J ;
Chadha, M ;
Coderre, JA ;
Diaz, AZ ;
Elowitz, EH ;
Iwai, J ;
Joel, DD ;
Liu, HGB ;
Ma, RM ;
Pendzick, N ;
Peress, NS ;
Shady, MS ;
Slatkin, DN ;
Tyson, GW ;
Wielopolski, L .
NEUROSURGERY, 1999, 44 (06) :1182-1192
[5]   Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: Trial design and early clinical results [J].
Coderre, JA ;
Elowitz, EH ;
Chadha, M ;
Bergland, R ;
Capala, J ;
Joel, DD ;
Liu, HYB ;
Slatkin, DN ;
Chanana, AD .
JOURNAL OF NEURO-ONCOLOGY, 1997, 33 (1-2) :141-152
[6]   Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991 [J].
Davis, FG ;
Freels, S ;
Grutsch, J ;
Barlas, S ;
Brem, S .
JOURNAL OF NEUROSURGERY, 1998, 88 (01) :1-10
[7]   Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture [J].
Gabel, D ;
Preusse, D ;
Haritz, D ;
Grochulla, F ;
Haselsberger, K ;
Fankhauser, H ;
Ceberg, C ;
Peters, HD ;
Klotz, U .
ACTA NEUROCHIRURGICA, 1997, 139 (07) :606-612
[8]  
Goodman JH, 2000, NEUROSURGERY, V47, P608
[9]   CLINICAL PHASE-I STUDY OF NA2B12H11SH (BSH) IN PATIENTS WITH MALIGNANT GLIOMA AS PRECONDITION FOR BORON NEUTRON-CAPTURE THERAPY (BNCT) [J].
HARITZ, D ;
GABEL, D ;
HUISKAMP, R .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (05) :1175-1181
[10]  
HASELSBERGER K, 1994, CANCER RES, V54, P6318